Whitehawk Therapeutics (WHWK) Net Equity Issued and Repurchased (2017 - 2020)

Whitehawk Therapeutics (WHWK) posted quarterly Net Equity Issued and Repurchased of $9.3 million for Q3 2020, up 40.42% quarter-over-quarter from $6.6 million in Q3 2018.

Whitehawk Therapeutics (WHWK) Net Equity Issued and Repurchased (2017 - 2020) Analysis & Trends

Whitehawk Therapeutics (WHWK) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $9.3 million the latest figure, recorded in Q3 2020.

  • In Q3 2020, Net Equity Issued and Repurchased changed N/A year-over-year to $9.3 million; the TTM figure through Dec 2022 stood at $9.3 million (changed 0.0% YoY), while the FY2021 annual figure was $155.0 million, up 1490.78% from the prior year.
  • Net Equity Issued and Repurchased rose to $9.3 million in Q3 2020 per WHWK's latest filing, from $6.6 million in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $40.2 million in Q1 2017 and bottomed at $2.0 in Q4 2017.
  • Historically, Net Equity Issued and Repurchased has averaged $14.0 million across 3 years, with a median of $8.0 million in 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Whitehawk Therapeutics 369.67 Mn 74.92 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2020 9.30 Mn
Sep 30, 2020 9.30 Mn
Sep 30, 2018 6.62 Mn
Sep 30, 2018 6.62 Mn
Dec 31, 2017 2.00
Dec 31, 2017 2.00
Mar 31, 2017 40.25 Mn
Mar 31, 2017 40.25 Mn